Cannabis Pharmaceuticals: Company With Ties To Groundbreaking Medical Developments Pursues Cannabinoid-Based Medicines
Phytanix Bio, a preclinical stage pharmaceutical company, has released an updated investor deck. The presentation showcases a business strategy aimed at developing new cannabinoid-based pharmaceuticals. The company, which has ties to historical pharmaceutical developments in the cannabis industry, was recently acquired by Chain Bridge I.
The new company, named Phytanix Inc., hopes to take a piece of a global cannabis pharmaceuticals market, with its estimated total market value of $3.4 billion.
“We are excited to share our new investor deck, which provides a comprehensive overview of Phytanix Bio’s vision and progress,” said Barrett Evans, CEO of Phytanix Bio. “Our team is dedicated to advancing our pipeline of cannabinoid-based medicines, and this presentation outlines …